Eye­ing clin­i­cal proof-of-con­cept for HER3 drug, Am­gen-part­nered biotech scores $125M for pre­ci­sion an­ti­bod­ies

When it comes to re­draw­ing the bound­aries of what pro­teins are drug­gable, small mol­e­cules have soaked up the spot­light. Hordes of new en­trants — in­hibitors, al­losteric mod­u­la­tors, de­graders — promise to make a big dif­fer­ence by hit­ting dis­ease-caus­ing pro­teins at the right spot.

Over the last five years a biotech out of Sin­ga­pore has been try­ing to show that the same ap­proach can be ap­plied to an­ti­bod­ies. Now No­vo Hold­ings is lead­ing a $125 mil­lion Se­ries C de­signed to push them to­ward clin­i­cal proof-of-con­cept.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER